TBI-166

TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) [1][2][3].

Product Specifications

CAS Number

[1353734-12-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/tbi-166.html

Purity

98.19

Solubility

DMSO : 9.09 mg/mL (ultrasonic; adjust pH to 3 with HCl)

Smiles

FC(F)(F)OC1=CC=C(N2C3=C/C(C(NC4=CC=CN=C4OC)=CC3=NC5=C2C=CC=C5)=N/C6CCC(OC)CC6)C=C1

Molecular Formula

C32H30F3N5O3

Molecular Weight

589.61

Precautions

H302, H315, H319

References & Citations

[1]Xu J, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63 (5) :e02155-18. |[2]Zhu H, et al. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother. 2021 Mar 18;65 (4) :e02164-20. |[3]Ding Y, et al. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2022 Sep 20;66 (9) :e0065822.